Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06427954 · ClinicalTrials.gov registry record · NA

Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer

A NA study of Lung Cancer, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
250
Enrollment target
3
Study locations

NCT06427954: Recruiting NA study of Lung Cancer, sponsored by Massachusetts General Hospital.

NCT06427954 is a NA study of Lung Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 250 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (73% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06427954, a NA study of Lung Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
250 participants
Enrollment target
3
Study locations

Study Summary

Multi-site randomized trial of the THRIVE digital health application versus usual care to evaluate the effect of THRIVE on quality of life (QOL), physical and psychological symptoms, coping, and self-efficacy in 250 patients with newly diagnosed advanced lung cancer.

Primary Outcome

Quality of Life (higher scores indicate better quality of life)

Conditions Studied

Interventions

  • BEHAVIORAL Digital Health App

Study Locations (3)

California

  • University of California Los Angeles - Los Angeles
  • Veteran Affairs Greater Los Angeles Health Care - Los Angeles

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2024-08-06
Est. Completion 2027-12
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT06427954 shows while recruiting

NCT06427954 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (73% lower).

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Digital Health App is the first listed.

NCT06427954 reports a single indexed study location in California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06427954 about?

NCT06427954 is a clinical study titled "Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer". Multi-site randomized trial of the THRIVE digital health application versus usual care to evaluate the effect of THRIVE on quality of life (QOL), physical and psychological symptoms, coping, and self-efficacy in 250 patients with newly diagnosed advanced lung cancer.

What is the current status of trial NCT06427954?

This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2024-08-06. Estimated completion is 2027-12.

What conditions does trial NCT06427954 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT06427954?

The interventions under investigation include: Digital Health App (BEHAVIORAL).

Who is sponsoring clinical trial NCT06427954?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06427954 being conducted?

This trial has 3 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06427954's enrollment target sits among peer trials

250 112th of 409 higher than 296 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06427954, the US trial registry maintained by the National Library of Medicine. NCT06427954 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.